02 July 2004
Pentoxyfilline as a cyclooxygenase (cox-2) inhibitor in experimental sepsisBogdan Modzelewski, Adam Janiak
Med Sci Monit 2004; 10(7): BR233-237 :: ID: 11697
Background:The aim of this study is to assess the impact of pentoxyphilline (PTX) on the pattern of serum concentrations of certain pro-inflammatory cytokines and their soluble receptors in relation to the animal’s survival period.Material/Methods:Diffuse peritonitis was elicited by means of cecal ligation and puncture (CLP) in 45 adult Wistar rats. The pattern of soluble TNF receptor p55 type 1 and p75 type 2 in reference to TNF-α and IL-1β concentration in animals with experimental diffuse peritonitis (EDP) was estimated. All animals were divided into 3 groups.Results:In both groups where animals received medication, the percentage of survival was higher than in the controls. An increase in CRP concentration was observed in all study animals. An increase in TNFa concentration was noted during the first 12 hours of the experiment. There was an increase in soluble TNFR p55 concentrations in all study groups until the 24[sup]th[/sup] hour of the experiment, then a decrease until the end of the observation period. The concentration of soluble TNF p75 receptor gradually increased over time in all groups. In group I a constant rise of IL-1b serum concentration was observed.Conclusions:Pentoxyphilline administration in animals in the early stage of diffuse peritonitis causes the TNFα serum concentration to decrease, but it does not improve the overall survival period. Late pentoxyphilline administration does not alter the course of diffuse peritonitis in rat.
Keywords: Antigens, CD - blood, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Cyclooxygenase Inhibitors - pharmacology, Injections, Intraperitoneal, Interleukin-1 - blood, Isoenzymes - antagonists & inhibitors, Pentoxifylline - pharmacology, Peritonitis - complications, Peritonitis - enzymology, Peritonitis - etiology, Peritonitis - immunology, Prostaglandin-Endoperoxide Synthases, Rats, Wistar, Receptors, Tumor Necrosis Factor - blood, Receptors, Tumor Necrosis Factor, Type I, Sepsis - drug therapy, Sepsis - enzymology, Sepsis - immunology, Time Factors, Tumor Necrosis Factor-alpha - analysis, Antigens, CD - blood, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Cyclooxygenase Inhibitors - pharmacology, Injections, Intraperitoneal, Interleukin-1 - blood, Isoenzymes - antagonists & inhibitors, Pentoxifylline - pharmacology, Peritonitis - immunology, Prostaglandin-Endoperoxide Synthases, Rats, Wistar, Receptors, Tumor Necrosis Factor - blood, Receptors, Tumor Necrosis Factor, Type I, Sepsis - immunology, Time Factors, Tumor Necrosis Factor-alpha - analysis
01 June 2023 : EditorialEditorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic Preparedness
Med Sci Monit 2023; 29:e941209
01 Jun 2023 : Clinical ResearchRoot Canal Numbers and Configurations in 1080 Permanent Canine Teeth in 270 Saudi Subjects Using Cone-Beam ...
Med Sci Monit In Press; DOI: 10.12659/MSM.940472
01 Jun 2023 : Clinical ResearchInternal Orifice Alloy Closure: A New Procedure for Treatment of Perianal Fistulizing Crohn’s Disease
Med Sci Monit In Press; DOI: 10.12659/MSM.940873
01 Jun 2023 : Clinical ResearchEffectiveness of Needle Aspiration versus Surgical Excision for Symptomatic Synovial Cysts of the Hip: A Si...
Med Sci Monit In Press; DOI: 10.12659/MSM.940187
01 Jun 2023 : Clinical ResearchInfluence of Insulin Resistance on Diabetes Nephropathy
Med Sci Monit In Press; DOI: 10.12659/MSM.939482
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : EditorialEditorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...
Med Sci Monit 2022; 28:e935952